PRME (Prime Medicine) EBIT: $-206.61 Mil (TTM As of Mar. 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine EBIT?

Prime Medicine PRME +2.09% 25 EBIT is $-206.61 Mil as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

Prime Medicine's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-50.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-206.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Prime Medicine's annualized ROC % for the quarter that ended in Mar. 2026 was -111.48%. Prime Medicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -140.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Prime Medicine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -37.34%.

Prime Medicine  (NAS:PRME) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Prime Medicine's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-202.616 * ( 1 - 0% )/( (186.442 + 177.046)/ 2 )
=-202.616/181.744
=-111.48 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=342.733 - 12.446 - ( 177.68 - max(0, 37.448 - 181.293+177.68))
=186.442

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=294.73 - 16.084 - ( 135.497 - max(0, 36.289 - 137.889+135.497))
=177.046

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Prime Medicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-202.616/( ( (146.749 + max(-25.698, 0)) + (142.15 + max(-25.351, 0)) )/ 2 )
=-202.616/( ( 146.749 + 142.15 )/ 2 )
=-202.616/144.4495
=-140.27 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.613) - (12.446 + 7.824 + 9.041)
=-25.698

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.392) - (16.084 + 7.32 + 4.339)
=-25.351

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Prime Medicine's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-206.612/553.376
=-37.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine EBIT Related Terms

Prime Medicine EBIT Historical Data

* Premium members only.

The historical data trend for Prime Medicine's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine EBIT Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -84.47 -116.54 -191.29 -202.47 -208.35

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.39 -53.38 -53.97 -48.61 -50.65

PRME vs IMMX, SGP, ACRS: EBIT Comparison

For the Biotechnology subindustry, Prime Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Prime Medicine's EV-to-EBIT falls into.


PRME
25GF Score
Prime Medicine Inc PRME
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-206.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-206.61 Mil mean?
Prime Medicine (PRME) has a EBIT of $-206.61 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Prime Medicine.
Is Prime Medicine's EBIT too high?
Prime Medicine's current EBIT is $-206.61 Mil. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EBIT compare to IMMX and SGP?
Prime Medicine's EBIT of $-206.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Prime Medicine. Prime Medicine's current EBIT is $-206.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EBIT of $-206.61 Mil. The current EBIT is $-206.61 Mil. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Prime Medicine (PRME), the current EBIT is $-206.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price